Smart Surgical Appliances secures investment for minimally invasive
surgery device
25 March 2009
Smart Surgical Appliances (SSA), a developer of medical devices to
improve the safety of minimally invasive surgery (MIS), has secured a
£330,000 round of investment from the National Endowment for Science,
Technology and the Arts (NESTA), Imperial Innovations, EF Investments,
and SSA Executive Chairman Paul Donnelly.
SSA is based on research emanating from the Department of Biosurgery
and Surgical Technology, within the Faculty of Medicine at Imperial
College London. The company focuses on producing sensor-enabled
technologies for minimally invasive surgery ie keyhole surgery,
endoscopic surgery and the newly emerging field of natural orifice
transluminal endoscopic surgery (NOTES).
A limitation with all MIS procedures is that the surgeon loses
dexterity and accuracy because of reduced proximity to the operative
site, leading to variable success rates and intra-operative
complications. SSA’s sensor-enabled instrumentation will, for the first
time, provide real-time sensing and feedback from the operative site
akin to ‘touch and feel’, preventing complications, improving judgement
and enabling reproducibility usually associated with experienced
surgeons.
SSA plans to use the investment to make further technical and
regulatory progress on their lead device, the SmartBougie, an
oesophageal dilator that measures the elasticity in the external walls
of the oesophagus.
Adam James of SSA explained the device: “During minimally invasive
surgery it is essential to know that you have dilated the area enough
and are not risking rupturing tissue. SmartBougie allows surgeons to
monitor dilatation more accurately than before and also allows for the
opposite scenario where surgeons are 'tightening' the region during a
surgical repair and want to make sure it is not too tight and not too
loose.”
The primary use for the product is in two procedures that require
dilatation and tightening of the oesophagus. During surgery to the
oesophagus, dilatation can present patient risks, with up to 5% of
procedures resulting in a ruptured oesophagus requiring further
emergency surgery and often involving opening the ribcage.
A second procedure which will benefit from the SmartBougie is known
as ‘Nissen Fundoplication’ — a procedure which is used to treat severe
cases of acid reflux. In this procedure part of the stomach is wrapped
around the oesophagus to tighten it. The current procedure has a high
re-operation rate of up to 20%, because the wrap is either too tight or
too loose.
In both cases, using the SmartBougie will provide the surgeon with
feedback to substantially reduce negative or ineffective outcomes.
Managing Director of NESTA Investments David Hunter said: “This kind
of cutting-edge technology can make a real difference to both
practitioners and patients involved in this type of delicate surgery and
is a great example of how early-stage investment can make a real,
tangible impact.”
NESTA made a pre-seed investment in the Company in March 2008, and as
part of that investment SSA were able to bring in the experience of Paul
Donnelly, previously CEO of a number of successful private equity backed
medical device companies, as Executive Chairman who is helping steer the
company towards financial success.